# Semaglutide or tirzepatide when injections are new to you

Medication choice and injection confidence are separate questions. Product format, training and medical suitability all matter.

Canonical: https://velri.co/blog/semaglutide-vs-tirzepatide-first-choice-needle-averse-new-mom
Publisher: Velri (https://velri.co/about)
Published: 2026-07-12
Updated: 2026-09-30
Editorial policy: https://velri.co/editorial-policy

Being new to injections does not, by itself, make semaglutide or tirzepatide the better choice. The medical decision and the administration decision need separate attention: which treatment fits, and how the exact prescribed product is used. [1][2]

A medication name alone does not tell you whether the prescription will arrive as a particular pen or vial.

## Compare the treatment, not just the device

Semaglutide activates GLP-1 receptors. Tirzepatide activates GIP and GLP-1 receptors. Both affect appetite and glucose regulation, but their mechanisms do not replace a review of eligibility, health history, tolerability and other medicines. [1][2]

Both labels include gastrointestinal effects and important warnings. Pregnancy plans and breastfeeding are especially relevant when the decision follows childbirth. Tirzepatide also has specific precautions for oral hormonal contraception. [1][2]

## Training should match what arrives

Instructions are product-specific. A prefilled pen demonstration is not sufficient training for a prescription supplied in a vial. The patient needs to recognize the actual formulation, device and prescribed directions, and know where questions go before using it. [1][2]

FDA has received reports of dosing errors with compounded semaglutide. Confusion about concentration, syringe measurement and instructions can cause serious harm. “I have used an injection before” is not enough to settle those details for a different product. [3]

## Make the practical plan visible

Before starting, the dispensing and prescribing teams should provide clear instructions for administration, storage and handling, and explain what to do if a dose is missed or something is unclear. These instructions should be written for the specific product rather than copied from an online example.

Compounded preparations are not FDA-approved or interchangeable with branded drugs. [3]

## Sources
[1] DailyMed - WEGOVY- semaglutide injection, solution
WEGOVY- semaglutide tablet. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
[2] DailyMed - ZEPBOUND- tirzepatide injection, solution
ZEPBOUND- tirzepatide injection, solution
ZEPBOUND KWIKPEN- tirzepatide injection, solution. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
[3] FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss | FDA. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/medications-containing-semaglutide-marketed-type-2-diabetes-or-weight-loss

## About this information
General health information, not personal medical advice, diagnosis or treatment. A prescription is required and is never guaranteed.
Velri is a brand operated by Velri Management LLC, a Nevada limited liability company. Velri is a non-clinical technology and administrative services company. Velri does not provide medical advice, diagnosis, treatment, or pharmacy services, and does not direct the clinical judgment of any provider.
All medical consultations and prescriptions are provided directly by independent provider groups (Online Medical Care, P.C.; TMD of Kansas, P.A.; TMD of Texas, P.A.; and TMD of CA, PC), by a provider licensed in your state. Velri does not employ providers. A prescription is issued only if a provider determines it is clinically appropriate in their independent medical judgment.
All prescription products are dispensed by independent, licensed pharmacies. Velri does not own, operate, or control any pharmacy and does not dispense medication. You may opt out of using a given provider group or pharmacy at any time.
Compounded medications are not reviewed or approved by the FDA for safety, effectiveness, or quality. Compounded products are not equivalent to or interchangeable with any FDA-approved brand-name drug. Availability varies by state.
Velri is cash-pay. We do not bill Medicare, Medicaid, or commercial insurance. Refunds and order problems are addressed in the Terms of Use; your rights under applicable law are not limited. State availability and clinical eligibility apply.
Velri and telehealth are not for medical emergencies. If you are experiencing an emergency, call 911.
These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
Care is available to eligible adults 18 and older in 47 states and D.C., United States only.
Notice of Privacy Practices: https://velri.co/privacy/notice-of-privacy-practices
Terms: https://velri.co/legal/terms
Provider group or pharmacy opt-out help: https://velri.co/contact and https://velri.co/standards#trust-support